Manage Tickers

Has my stock been accused of fraud?Join over 160k users who know.

Ticker Price Change($) Change(%) Shares Volume Prev Close Open Gain($) Gain(%)
Ticker Status Jurisdiction Filing Date CP Start CP End CP Loss Deadline
Ticker Case Name Status CP Start CP End Deadline Settlement Amt
Ticker Name Date Analyst Firm Up/Down Target ($) Rating Change Rating Current
Analyst Rating Guide

News

Back

Atara Biotherapeutics Q2 2024 GAAP EPS $(3.10) Misses $(1.56) Estimate, Sales $28.64M Miss $39.99M Estimate

Author: Benzinga Newsdesk | August 12, 2024 05:15pm
Atara Biotherapeutics (NASDAQ:ATRA) reported quarterly losses of $(3.10) per share which missed the analyst consensus estimate of $(1.56) by 98.72 percent. The company reported quarterly sales of $28.64 million which missed the analyst consensus estimate of $39.99 million by 28.38 percent. This is a 2.89K percent increase over sales of $957.00 thousand the same period last year.

Posted In: ATRA


CORE & Plaid

CORE Finalist

CLASS ACTION DEADLINES - JOIN NOW!

NEW CASE INVESTIGATION

CORE Finalist